Loss of WWOX Contributes to Cisplatin Resistance in Triple-negative Breast Cancer Cells by Modulating MiR-182 and MiR-214

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2024 Oct 30

PMID 39473747

Authors

Bahadir Batar

Elif Serdal

Berna Erdal

Hasan Ogul

Affiliations

Soon will be listed here.

Abstract

Background/aim: WW domain-containing oxidoreductase (WWOX) loss frequently occurs in triple-negative breast cancer (TNBC). WWOX loss enhances cisplatin resistance in TNBC patients. Although WWOX loss has an effect on the selection of a DNA repair pathway that contributes to enhanced mutagenesis, the downstream expression changes in resistant cancer cells have not been fully explored. This study aimed to investigate the potential role of microRNAs (miRNAs) in the regulation of cisplatin resistance in WWOX-deficient TNBC cells.

Materials And Methods: Transient transfections were performed to overexpress WWOX in MDA-MB-231 cells. WWOX-overexpressing MDA-MB-231 cells were determined by western blot. Expression profiling of the miRNA was assessed via real-time polymerase chain reaction.

Results: miRNA expression profiling of WWOX-deficient and -sufficient MDA-MB-231 cells revealed that miR-182 upregulation and miR-214 downregulation were markedly positively associated with cisplatin resistance of WWOX-deficient MDA-MB-231 cells. An elevated expression of miR-182 and decreased expression of miR-214 may contribute to cisplatin resistance in WWOX-absent MDA-MB-231 cells by signaling pathway dysregulation of DNA repair/apoptosis/ protein kinase B (AKT).

Conclusion: The results emphasize that WWOX deficiency promotes resistance to cisplatin in TNBC cells and the possible predicting biomarker of WWOX for resistance to cisplatin.

References

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

Fang C, Chen Y, Wu N, Yin J, Li X, Huang H . MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 2017; 7:40384. PMC: 5225486. DOI: 10.1038/srep40384. View

Aldaz C, Ferguson B, Abba M . WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta. 2014; 1846(1):188-200. PMC: 4151823. DOI: 10.1016/j.bbcan.2014.06.001. View

Uhlmann S, Mannsperger H, Zhang J, Horvat E, Schmidt C, Kublbeck M . Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012; 8:570. PMC: 3293631. DOI: 10.1038/msb.2011.100. View

Betel D, Wilson M, Gabow A, Marks D, Sander C . The microRNA.org resource: targets and expression. Nucleic Acids Res. 2007; 36(Database issue):D149-53. PMC: 2238905. DOI: 10.1093/nar/gkm995. View

Maragkakis M, Reczko M, Simossis V, Alexiou P, Papadopoulos G, Dalamagas T . DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 2009; 37(Web Server issue):W273-6. PMC: 2703977. DOI: 10.1093/nar/gkp292. View

Yan H, Xu J, Fang L, Qiu Y, Lin X, Huang H . Ectopic expression of the WWOX gene suppresses stemness of human ovarian cancer stem cells. Oncol Lett. 2015; 9(4):1614-1620. PMC: 4356412. DOI: 10.3892/ol.2015.2971. View

Ludes-Meyers J, Bednarek A, Popescu N, Bedford M, Aldaz C . WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res. 2003; 100(1-4):101-10. PMC: 4150470. DOI: 10.1159/000072844. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

10.

Ekizoglu S, Bulut P, Karaman E, Kilic E, Buyru N . Epigenetic and genetic alterations affect the WWOX gene in head and neck squamous cell carcinoma. PLoS One. 2015; 10(1):e0115353. PMC: 4303423. DOI: 10.1371/journal.pone.0115353. View

11.

Qin J, Luo M, Qian H, Chen W . Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014; 538(2):342-7. DOI: 10.1016/j.gene.2013.12.043. View

12.

Seidl C, Panzitt K, Bertsch A, Brcic L, Schein S, Mack M . MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 2019; 469:266-276. DOI: 10.1016/j.canlet.2019.10.044. View

13.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

14.

Cataldo A, Cheung D, Balsari A, Tagliabue E, Coppola V, Iorio M . miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2015; 7(1):786-97. PMC: 4808033. DOI: 10.18632/oncotarget.6381. View

15.

Ning F, Wang F, Li M, Yu Z, Hao Y, Chen S . MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol. 2014; 9:143. PMC: 4108001. DOI: 10.1186/1746-1596-9-143. View

16.

Xiao M, Guo J, Xie L, Yang C, Gong L, Wang Z . Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1. Mol Cancer Res. 2019; 18(3):436-447. DOI: 10.1158/1541-7786.MCR-18-1369. View

17.

Wong N, Wang X . miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2014; 43(Database issue):D146-52. PMC: 4383922. DOI: 10.1093/nar/gku1104. View

18.

Li W, Wang W, Ding M, Zheng X, Ma S, Wang X . MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell Int. 2016; 16:30. PMC: 4828824. DOI: 10.1186/s12935-016-0305-6. View

19.

Schrock M, Batar B, Lee J, Druck T, Ferguson B, Cho J . Wwox-Brca1 interaction: role in DNA repair pathway choice. Oncogene. 2016; 36(16):2215-2227. PMC: 5398941. DOI: 10.1038/onc.2016.389. View

20.

Karras J, Schrock M, Batar B, Huebner K . Fragile Genes That Are Frequently Altered in Cancer: Players Not Passengers. Cytogenet Genome Res. 2017; 150(3-4):208-216. DOI: 10.1159/000455753. View